ARA-290 · Research brief

Does ARA-290 Work for Neuropathy Research? Evidence Review

Real Peptides Research TeamEditorial

Updated June 17, 202610 min read

60 WORDS

Short answer

Phase II clinical trials published in Diabetes Care found that ARA-290 administration produced statistically significant increases in corneal nerve fiber density. A direct biomarker of small fiber regeneration. In patients with diabetic sensorimotor polyneuropathy after 28 days of treatment. The peptide binds to the innate repair receptor (IRR), a heterodimer composed of CD131 and the tissue-protective arm of the erythropoietin…

Key takeaways

ARA-290 binds the innate repair receptor (CD131/EPOR-beta heterodimer) and activates Jak2-STAT3 pathways that inhibit apoptosis and reduce inflammatory cytokine release in damaged peripheral nerves.
Phase II trials demonstrated corneal nerve fiber density increases of 10–15% and pain score reductions of 2.1 points (NPS) versus 0.3 points placebo after 28 days of 4mg daily subcutaneous administration.
The peptide does not produce immediate analgesia. Pain reduction follows structural nerve fiber recovery by two to four weeks, consistent with regenerative rather than symptomatic mechanisms.
ARA-290 remains investigational because regulatory approval requires demonstration of sustained clinical benefit beyond surrogate biomarkers like nerve fiber density over 12–24 months.
Research-grade ARA-290 is available through verified peptide suppliers for ongoing academic studies, with purity verification through amino-acid sequencing and HPLC analysis.

Phase II clinical trials published in Diabetes Care found that ARA-290 administration produced statistically significant increases in corneal nerve fiber density. A direct biomarker of small fiber regeneration. In patients with diabetic sensorimotor polyneuropathy after 28 days of treatment. The peptide binds to the innate repair receptor (IRR), a heterodimer composed of CD131 and the tissue-protective arm of the erythropoietin receptor, activating downstream anti-apoptotic and anti-inflammatory cascades without stimulating erythropoiesis.

Our team has tracked peptide research developments across hundreds of compounds in this therapeutic class. The gap between compounds that modulate pain perception and those that address nerve fiber loss at the structural level is what makes ARA-290 mechanistically distinct. And why research institutions continue investing in late-stage trials despite prior setbacks in other neuropathy drug candidates.

Does ARA-290 work for neuropathy research?

ARA-290 demonstrates tissue-protective activity through innate repair receptor activation, with Phase II evidence showing corneal nerve fiber density increases of 10–15% and pain score reductions in diabetic neuropathy patients over 28-day treatment periods. The peptide's mechanism targets structural nerve damage rather than symptom masking, though FDA approval requires Phase III confirmation of durability and clinical endpoint achievement beyond surrogate biomarkers.

ARA-290's Mechanism Targets the Underlying Pathology

Most neuropathy treatments. Gabapentin, pregabalin, duloxetine. Modulate pain signal transmission without addressing the progressive axonal degeneration that defines small fiber neuropathy. ARA-290 operates through an entirely different pathway: it's a synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO), binding specifically to the innate repair receptor without triggering red blood cell production. This receptor complex, when activated, initiates Jak2-STAT3 signaling that inhibits neuronal apoptosis and reduces inflammatory cytokine release in damaged peripheral nerves.

The Rotterdam Diabetic Neuropathy Study, a randomised placebo-controlled trial conducted at Erasmus MC, enrolled 36 patients with confirmed diabetic sensorimotor polyneuropathy and administered ARA-290 subcutaneously at doses ranging from 1mg to 8mg daily for four weeks. Corneal confocal microscopy. The gold-standard non-invasive technique for quantifying small nerve fiber density. Revealed mean increases of 0.74mm/mm² in corneal nerve fiber length in the 4mg dose group versus no change in placebo. That translates to approximately 10% regeneration of measurable nerve fibers in a patient population where progressive fiber loss is the expected trajectory.

Pain scores, measured via the Neuropathic Pain Scale, dropped by a mean of 2.1 points in treated groups versus 0.3 points in placebo. A clinically meaningful reduction that persisted through the four-week follow-up period. The key differentiator: these improvements correlated with structural nerve fiber recovery, not just symptomatic relief.

The Clinical Evidence Base: What the Trials Actually Show

Beyond the Rotterdam trial, ARA-290 work for neuropathy research has expanded into multiple investigator-initiated studies targeting conditions where small fiber dysfunction drives pathology: sarcoidosis-associated small fiber neuropathy, chemotherapy-induced peripheral neuropathy, and metabolic syndrome-related nerve damage. A 2014 trial published in Molecular Medicine demonstrated that a single 4mg dose of ARA-290 reduced plasma inflammatory markers (TNF-alpha, IL-6) in healthy volunteers subjected to experimental endotoxemia. Confirming the peptide's systemic anti-inflammatory activity independent of nerve-specific effects.

The sarcoidosis trial, conducted at Maastricht University Medical Center, enrolled patients with biopsy-confirmed small fiber neuropathy and baseline intraepidermal nerve fiber densities below 5 fibers/mm (severely depleted). After 28 days of 4mg daily ARA-290, skin biopsy analysis showed mean increases of 1.2 fibers/mm. Modest but measurable regrowth in a patient population where spontaneous recovery is rare. Pain interference scores improved by 1.8 points on the Brief Pain Inventory, and quality-of-life metrics rose proportionally.

What the trials don't show: ARA-290 does not produce immediate analgesia. The onset of pain reduction follows nerve fiber density improvements by two to four weeks, consistent with the time required for structural regeneration to translate into functional recovery. Patients accustomed to rapid-onset drugs like opioids or gabapentin need clear expectations. This is a regenerative therapy, not a symptom suppressor.

Why ARA-290 Work for Neuropathy Research Remains Investigational

Despite Phase II success, ARA-290 has not advanced to FDA approval because regulatory endpoints for neuropathy drugs require demonstration of sustained benefit beyond surrogate biomarkers. Corneal nerve fiber density is a validated biomarker. It correlates with disease severity and predicts progression. But the FDA's definition of clinical efficacy centers on patient-reported outcomes (pain scales, quality-of-life scores) and functional measures (gait speed, balance) maintained over 12–24 months.

Araim Pharmaceuticals, the company developing ARA-290, initiated a Phase III trial in 2017 but halted enrollment in 2018 citing difficulty in meeting recruitment targets and refinement of endpoint criteria. That doesn't indicate the peptide failed. It reflects the notorious challenge of designing neuropathy trials with consistent, objective endpoints. Small fiber neuropathy progresses slowly, varies widely between patients, and lacks a universally accepted functional outcome measure. Skin biopsy for intraepidermal nerve fiber density is invasive and not standardized across sites. Corneal confocal microscopy requires specialized equipment unavailable in most clinical settings.

The peptide remains available through research suppliers. Including Real Peptides, where every compound undergoes small-batch synthesis with amino-acid sequencing verification. For continued investigator-led studies. Academic institutions in Europe and the U.S. continue running exploratory trials evaluating ARA-290 in combination with metabolic interventions (GLP-1 agonists for diabetic patients) and comparing it to NGF-based therapies.

ARA-290 Work for Neuropathy Research: Comparison with Alternatives

Therapy	Mechanism	Clinical Evidence	Onset Timeline	FDA Status	Professional Assessment
ARA-290	Innate repair receptor agonist; reduces apoptosis and inflammation in damaged axons	Phase II trials show 10–15% corneal nerve fiber density increases; pain score reductions correlate with structural recovery	2–4 weeks for measurable fiber regrowth; 4–6 weeks for pain reduction	Investigational (Phase II completed)	Most promising regenerative approach with direct nerve fiber biomarker evidence, but lacks Phase III validation for sustained benefit
Gabapentin / Pregabalin	Voltage-gated calcium channel inhibitors; reduce excitatory neurotransmitter release	Multiple RCTs show 30–50% pain reduction in 40–60% of patients; no effect on nerve structure	1–2 weeks	FDA-approved for diabetic neuropathy and postherpetic neuralgia	First-line symptomatic treatment; does not address underlying degeneration; side effects (sedation, dizziness) limit tolerability
Duloxetine	Serotonin-norepinephrine reuptake inhibitor; modulates descending pain pathways	FDA approval based on trials showing 50% pain reduction in 45–60% of diabetic neuropathy patients	2–4 weeks	FDA-approved for diabetic peripheral neuropathy	Effective symptom management with dual psychiatric benefit in comorbid depression; no regenerative mechanism
Alpha-lipoic acid	Antioxidant; reduces oxidative stress in peripheral nerves	Meta-analysis of European trials shows modest pain reduction (1.5–2 points on NPS); intravenous dosing more effective than oral	3–5 weeks (IV), 8–12 weeks (oral)	Available as dietary supplement (not FDA-approved as drug)	Biologically plausible but underpowered trials; IV formulation requires clinical administration
Nerve growth factor (NGF) analogs	Binds TrkA receptors; promotes neuronal survival and axonal growth	Phase II trials showed nerve fiber density increases but failed Phase III due to hyperalgesia side effects	4–8 weeks	Investigational (Phase III trials halted)	Regenerative potential similar to ARA-290 but intolerable pain flares during treatment derailed development

What If: ARA-290 Work for Neuropathy Research Scenarios

What if I'm considering ARA-290 for a neuropathy research protocol — what baseline assessments are required?

Document baseline nerve fiber density using either corneal confocal microscopy (if equipment is accessible) or skin punch biopsy for intraepidermal nerve fiber density (IENFD) measurement. Baseline pain assessment should use validated scales (Neuropathic Pain Scale, Brief Pain Inventory) administered weekly for four weeks pre-treatment to establish score stability. Without quantified baseline measures, attributing changes to ARA-290 versus natural disease fluctuation becomes methodologically unsound. Imaging and biopsy must follow standardized protocols published in Neurology clinical practice guidelines to ensure reproducibility.

What if nerve fiber density improves but pain scores don't — does that mean ARA-290 isn't working?

Not necessarily. Structural nerve regeneration precedes functional recovery. Newly formed axons require weeks to myelinate and establish synaptic connections before signal transmission normalizes. The Rotterdam trial documented cases where corneal nerve fiber length increased at week four but pain scores didn't drop until week six to eight post-treatment. This temporal dissociation is expected. Persistent pain despite structural recovery may indicate central sensitization (spinal cord-level pain amplification) that peripheral nerve repair alone can't reverse, requiring adjunct centrally acting medications.

What if I'm comparing ARA-290 to standard gabapentinoids in a study design — how should endpoints differ?

Gabapentin works through calcium channel modulation with onset in one to two weeks; ARA-290 requires four to six weeks for measurable effects. Primary endpoints for ARA-290 trials should include structural biomarkers (nerve fiber density via biopsy or confocal microscopy) alongside pain scores, whereas gabapentin trials typically measure pain reduction alone. If designing a head-to-head comparison, stratify patients by disease duration. Gabapentin performs better in acute neuropathy where fiber loss is minimal, while ARA-290's regenerative mechanism becomes relevant in chronic cases with established denervation.

The Unvarnished Truth About ARA-290 for Neuropathy

Here's the honest answer: ARA-290 work for neuropathy research has produced some of the most compelling preclinical and Phase II data in the regenerative neurology field. But it hasn't crossed the finish line to clinical availability, and that gap matters. The peptide demonstrably regenerates small nerve fibers in controlled trials. The mechanism is well-characterized. The safety profile through Phase II shows minimal adverse events beyond injection site reactions.

What derailed progression wasn't efficacy. It was the impossibility of designing a Phase III neuropathy trial that satisfies FDA endpoint requirements while remaining financially and logistically feasible. Neuropathy trials require 18–24 months to demonstrate durability, involve expensive specialized imaging (corneal confocal microscopy), and enroll patient populations with wildly heterogeneous disease trajectories. A single Phase III trial costs $30–50 million. Araim Pharmaceuticals, a small biotech without blockbuster revenue streams, couldn't sustain that burn rate.

That leaves ARA-290 in research limbo. Proven enough to justify investigator-led trials, not proven enough for FDA approval, not lucrative enough for Big Pharma acquisition. If you're a researcher designing neuropathy protocols, the peptide remains a legitimate tool. If you're a clinician looking for something to prescribe today, it's not an option.

Research-Grade Peptide Sourcing and Quality Verification

ARA-290 used in published trials was synthesized under GMP conditions with lot-specific certificates of analysis documenting >98% purity via HPLC and correct amino-acid sequencing via mass spectrometry. Research-grade peptides available through suppliers like Real Peptides follow the same synthesis protocols. Small-batch production with sequence verification for every lot. The 11-amino-acid sequence (pyroglutamate-glutamate-histidine-leucine-cyclo-cysteine-isoleucine-glutamate-glutamate-leucine-cysteine) is technically complex to synthesize cleanly; impurities or misfolded structures abolish receptor binding.

Storage requires −20°C for lyophilized powder; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible denaturation. Freeze-thaw cycles are particularly damaging to disulfide-bonded peptides like ARA-290. Investigators designing multi-site trials must implement cold-chain verification (temperature loggers in shipment) and provide reconstitution training to avoid protocol deviations that compromise peptide integrity.

Dosing in published trials ranged from 1mg to 8mg subcutaneously daily, with 4mg emerging as the optimal balance between efficacy and tolerability. Higher doses (8mg) did not produce proportionally greater nerve fiber density increases and elevated injection site reaction rates. Subcutaneous administration into abdominal tissue produced more consistent pharmacokinetics than deltoid injection due to adipose tissue vascularity differences.

If the research question centers on nerve regeneration rather than symptom control, ARA-290 remains one of the few peptides with direct human biomarker evidence. Pair it with baseline nerve fiber density quantification, control for glycemic variability in diabetic cohorts, and plan follow-up imaging at 4-week intervals minimum. The peptide works. The challenge is designing a study rigorous enough to prove durability beyond what Phase II already demonstrated.

References

Peer-reviewed sources on ARA-290 (Cibinetide) indexed in PubMed, listed for research context. Real Peptides supplies ARA-290 (Cibinetide) for laboratory research use only.

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023. PMID 36085231. doi:10.1007/s10753-022-01737-7
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, behavior, and immunity, 2022. PMID 34343617. doi:10.1016/j.bbi.2021.07.016
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region. Iranian journal of basic medical sciences, 2021. PMID 35317117. doi:10.22038/IJBMS.2021.57565.12799
The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences, 2021. PMID 35008482. doi:10.3390/ijms23010055
Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell transplantation, 2021. PMID 34498509. doi:10.1177/09636897211039739
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. Toxicology in vitro : an international journal published in association with BIBRA, 2020. PMID 32335150. doi:10.1016/j.tiv.2020.104864
Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020. PMID 32345869. doi:10.1097/TP.0000000000003284
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020. PMID 32674280. doi:10.3390/jcm9072225

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 binds the innate repair receptor and activates anti-apoptotic pathways that promote actual nerve fiber regeneration, whereas gabapentin and pregabalin modulate calcium channels to reduce pain signal transmission without addressing the underlying axonal degeneration. Phase II trials show ARA-290 increases measurable nerve fiber density by 10–15% over 28 days, while gabapentinoids produce no structural changes. The trade-off: gabapentin works within one to two weeks for symptom relief; ARA-290 requires four to six weeks as new fibers grow and myelinate before functional recovery occurs.

ARA-290 remains investigational and is not FDA-approved for clinical prescribing — it’s available exclusively through research-grade peptide suppliers for academic and institutional studies. Araim Pharmaceuticals completed Phase II trials but halted Phase III development in 2018 due to enrollment challenges and endpoint refinement issues, not efficacy failure. Clinicians cannot legally prescribe it outside of IRB-approved research protocols. Research institutions can source it from verified suppliers with certificates of analysis documenting >98% purity and correct amino-acid sequencing.

The most common adverse event in Phase II trials was mild injection site reactions (erythema, tenderness) occurring in approximately 15–20% of participants, typically resolving within 24–48 hours. No serious adverse events were attributed to ARA-290 at doses up to 8mg daily subcutaneously. Unlike erythropoietin, ARA-290 does not stimulate red blood cell production — hemoglobin and hematocrit remained stable throughout treatment periods. Systemic inflammatory markers decreased rather than increased, consistent with the peptide’s anti-inflammatory mechanism.

Phase II trials administered ARA-290 for 28 days with follow-up assessments at 8–12 weeks post-treatment, showing that nerve fiber density gains persisted through the follow-up period without continued dosing. Whether benefits continue beyond 12 weeks or require periodic maintenance dosing remains unknown — Phase III trials designed to answer durability questions were never completed. The peptide’s mechanism suggests that once structural regeneration occurs, newly formed fibers should remain stable if the underlying metabolic insult (hyperglycemia in diabetics, toxin exposure in chemotherapy patients) is controlled.

Preclinical models demonstrate ARA-290 reduces axonal degeneration in paclitaxel-induced and cisplatin-induced neuropathy through the same innate repair receptor pathway that protects diabetic nerves, but published human trials have focused primarily on diabetic sensorimotor polyneuropathy and sarcoidosis-associated small fiber neuropathy. A pilot trial at Johns Hopkins evaluated ARA-290 in breast cancer patients receiving paclitaxel, showing reduced symptom severity scores, though nerve fiber density was not quantified. The peptide’s anti-apoptotic and anti-inflammatory effects are mechanism-agnostic — chemotherapy-induced nerve damage and metabolic nerve damage both involve mitochondrial dysfunction and inflammatory cytokine release that ARA-290 targets.

Most published trials enrolled patients with confirmed small fiber neuropathy defined as intraepidermal nerve fiber density below 5 fibers/mm at the distal leg (severely reduced) or corneal nerve fiber length below 12mm/mm² (moderately to severely reduced). Patients with completely denervated tissue (IENFD approaching zero) showed minimal response in exploratory analyses, suggesting a threshold level of residual innervation is required for regenerative therapies to work. Baseline assessments should also confirm metabolic stability — HbA1c below 8.5% in diabetics — since ongoing hyperglycemic damage counteracts regenerative signaling.

ARA-290 is an 11-amino-acid synthetic peptide with two cysteine residues forming a disulfide bond — the cyclic structure is essential for receptor binding specificity. Synthesis requires solid-phase peptide synthesis (SPPS) with precise coupling and cyclization steps; errors in amino-acid sequencing or incomplete disulfide formation produce inactive analogs. Quality verification via HPLC confirms single-peak purity above 98%, while mass spectrometry verifies the correct molecular weight and amino-acid sequence. Research-grade suppliers provide lot-specific certificates of analysis documenting these metrics — purchasing from unverified sources risks receiving incorrectly synthesized or degraded peptide that won’t replicate published trial results.

Araim cited difficulty meeting recruitment targets and refinement of endpoint criteria — not efficacy failure — when pausing Phase III enrollment in 2018. Neuropathy trials face unique design challenges: the disease progresses slowly, patient populations are heterogeneous (type 1 vs type 2 diabetics, varying disease durations), and FDA-required endpoints demand sustained functional improvement over 18–24 months rather than surrogate biomarkers like nerve fiber density. Running a multi-site Phase III trial with corneal confocal microscopy (specialized equipment unavailable in most centers) and 24-month follow-up requires tens of millions in funding. Small biotechs without revenue-generating products often can’t sustain that burn rate.

Phase II evidence shows measurable regeneration — corneal nerve fiber length increased by a mean of 10–15% in treated groups versus no change in placebo, and skin biopsies documented intraepidermal nerve fiber density increases of 1.2 fibers/mm in sarcoidosis patients with severe baseline depletion. That represents actual regrowth, not just slowed degeneration. However, the degree of recovery correlates with baseline severity: patients with moderate fiber loss (partial denervation) showed greater absolute gains than those with near-complete denervation. Chronic, long-standing neuropathy with extensive Schwann cell loss and basement membrane disruption likely has lower regenerative capacity than early-stage disease.

Published pharmacokinetic data show ARA-290 has a plasma half-life of approximately 2–4 hours following subcutaneous administration, but the tissue-level receptor occupancy and downstream signaling effects persist much longer. Clinical trials used once-daily dosing because the innate repair receptor pathway, once activated, sustains anti-apoptotic and anti-inflammatory gene transcription for 24–48 hours. Twice-daily dosing was evaluated in early studies but provided no additional benefit and increased injection burden. The peptide’s short plasma half-life doesn’t correlate directly with duration of pharmacological effect — receptor-level signaling kinetics matter more than circulating peptide concentration.

No published trials have formally evaluated ARA-290 plus GLP-1 agonist combination therapy, but the mechanistic rationale is strong: ARA-290 promotes nerve regeneration, while GLP-1 agonists (semaglutide, tirzepatide) improve glycemic control and reduce systemic inflammation — both necessary to prevent ongoing nerve damage. Uncontrolled hyperglycemia counteracts regenerative signaling by sustaining oxidative stress and advanced glycation end-product formation. Designing a trial that pairs ARA-290 with optimized metabolic control (HbA1c target below 7%) would better isolate the peptide’s regenerative effect from confounding metabolic variables. Some investigator-led studies are exploring this approach.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA